Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04551885
Study type Interventional
Source Fate Therapeutics
Status Active, not recruiting
Phase Phase 1
Start date September 7, 2020
Completion date January 25, 2037

See also
  Status Clinical Trial Phase
Recruiting NCT05054348 - Phase 1b Study of IO-108 as Monotherapy and in Combination With a PD-1 Inhibitor in Solid Tumors Phase 1
Recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Recruiting NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies Phase 1/Phase 2
Not yet recruiting NCT05865990 - HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease Phase 2
Withdrawn NCT05071846 - MVX-ONCO-2 in Advanced Solid Tumors Phase 1
Recruiting NCT05607199 - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics Phase 1
Recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Recruiting NCT05276284 - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Phase 1/Phase 2
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Recruiting NCT05435339 - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting NCT04092673 - Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT05586321 - Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT04899505 - Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
Active, not recruiting NCT04597541 - A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04130516 - Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Phase 1/Phase 2
Recruiting NCT04041310 - Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Phase 1/Phase 2